These include KIAA1549::BRAF fusions in low-grade gliomas, H3 K28M/I mutations in diffuse midline gliomas, H3 G35R/V mutations in diffuse hemispheric gliomas, somatic TP53 mutations in high-grade gliomas, and MYCN amplification in neuroblastoma, for example. This evidence concerns the gene KIAA1549 and central nervous system cancer.